October 7, 2020

08 Oct 2020 | All | Celltrion | Korea Biomedical Review reports Celltrion has received approval for Ph III trials of CT-P39 (proposed omalizumab biosimilar).

14 Jul 2020 | All | Celltrion | In an interview with the Centre for Biosimilars, Celltrion's head of marketing,...

Please reload

Biosimilars bulletin 

October 4, 2020

Please reload

Search by tags